TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37222865

Group type: EXPERIMENTAL
Intervention: Patients' perspectives
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Significant others' perspectives
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: GPs' perspectives
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: District nurses' perspectives
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Hospital physicians' perspectives
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement between patient-significant other dyads
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement between GP-hospital physician dyads
Number of subjects: 165
Study: 37223015

Group type: EXPERIMENTAL
Intervention: ICG angiography-guided thyroidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 0
Study: 37223263

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 37223390

Group type: EXPERIMENTAL
Intervention: Active iTBS over the DMPFC
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham iTBS-synchronized transcutaneous electrical nerve stimulation
Number of subjects: 49
Study: 37223438

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 37223439

Group type: EXPERIMENTAL
Intervention: AXA1125 (33.9 g, administered orally in a liquid suspension twice daily for four weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (matching placebo administered orally in a liquid suspension twice daily for four weeks)
Number of subjects: 41
Study: 37223507

Group type: EXPERIMENTAL
Intervention: Low-dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6
Study: 37223611

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 120

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 120
Study: 37223613

Group type: EXPERIMENTAL
Intervention: Gas chromatography-mass spectrometry (GC-MS) for measuring breath VOCs in obese children with dyslipidemia.
Number of subjects: 82
Study: 37223666

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg OD for 14 days
Number of subjects: 660

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study: 37223900

Group type: EXPERIMENTAL
Intervention: RAMP-HT
Number of subjects: 212707

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 212707
Study: 37223933

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5815
Study: 37223971

Group type: EXPERIMENTAL
Intervention: MY-Skills online intervention (16 online synchronous yoga sessions over 8 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MY-Skills online intervention
Number of subjects: 18
Study: 37223968

Group type: EXPERIMENTAL
Intervention: MoveTogether app
Number of subjects: 10
Study: 37223981

Group type: EXPERIMENTAL
Intervention: Autonomic Modulation Training (AMT) intervention, which includes 1 session of baseline survey measures, 6 weekly sessions of HRV biofeedback training, and 1 follow-up session.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Autonomic Modulation Training (AMT) intervention.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (prepost assessment only).
Number of subjects: 250
Study: 37224065

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lidocaine and Ketamine combination
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lidocaine alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketamine alone
Number of subjects: 82
Study: 37224071

Group type: EXPERIMENTAL
Intervention: Certain PFAS (including PFHxS, PFOS, PFDA, PFUnDA)
Number of subjects: 2621

Group type: EXPERIMENTAL
Intervention: PFAS
Number of subjects: 2621
Study: 37224109

Group type: EXPERIMENTAL
Intervention: Intake of chocolate (white, milk, dark)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intake of white chocolate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intake of chocolate (any type)
Number of subjects: 30
Study: 37224125

Group type: EXPERIMENTAL
Intervention: Female and informational (FI)
Number of subjects: 3437

Group type: EXPERIMENTAL
Intervention: Male and motivational (MM)
Number of subjects: 3437

Group type: EXPERIMENTAL
Intervention: Female and motivational (FM)
Number of subjects: 3437

Group type: COMPARATOR
Intervention: Male and informational (MI)
Number of subjects: 3437

Group type: EXPERIMENTAL
Intervention: Female arms (pooled)
Number of subjects: 3437

Group type: EXPERIMENTAL
Intervention: Motivational arms (pooled)
Number of subjects: 3437
Study: 37224142

Group type: EXPERIMENTAL
Intervention: Assistive technology approach using smart device software and step-by-step pictures (the MapHabit System)
Number of subjects: 26
Study: 37224162

Group type: EXPERIMENTAL
Intervention: Integrated exercise and cardiovascular health education programme (12-week duration, includes group-based health education talk, booklet, lecture video, tailor-made exercise video, and text messaging booster intervention).
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo intervention (includes talk on basic health issues, lecture video, and corresponding leaflet).
Number of subjects: 190
Study: 37224198

Group type: EXPERIMENTAL
Intervention: 45 mg of upadacitinib
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: 15 mg of upadacitinib
Number of subjects: 1523

Group type: EXPERIMENTAL
Intervention: 30 mg of upadacitinib
Number of subjects: 1523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1523
Study: 37224196

Group type: EXPERIMENTAL
Intervention: NmCV-5
Number of subjects: 1800
Study: 37224228

Group type: EXPERIMENTAL
Intervention: L19TNF in combination with CCNU
Number of subjects: 5
Study: 37224232

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 minutes, twice per week)
Number of subjects: 403

Group type: COMPARATOR
Intervention: ECT (three times per week)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 403
Study: 37224404

Group type: EXPERIMENTAL
Intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Number of subjects: 126
Study: 37224793

Group type: EXPERIMENTAL
Intervention: EHR heart health tool (R01CA226078 & UG1CA189824)
Number of subjects: 55
Study: 37224883

Group type: EXPERIMENTAL
Intervention: Dual Pathway Inhibition (DPI) with Aspirin plus Vascular-Dose Rivaroxaban
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy (DAPT) with Aspirin (81 mg/qd) plus a P2Y12 inhibitor
Number of subjects: 90
Study: 37224994

Group type: EXPERIMENTAL
Intervention: Amazon Alexa (voice-assisted AI system)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Health care personnel
Number of subjects: 52
Study: 37225045

Group type: EXPERIMENTAL
Intervention: RV function measures (absolute RV free wall longitudinal strain (RVFWLS) and RVFWLS/PASP ratio)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: RVFWLS
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: RVFWLS/PASP ratio
Number of subjects: 528

Group type: COMPARATOR
Intervention: sacubitril/valsartan treatment
Number of subjects: 528
Study: 37225124

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (PRO) for 6 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (PRO)
Number of subjects: 48
Study: 37225248

Group type: EXPERIMENTAL
Intervention: eCDSS intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: Usual care (discussion about medication)
Number of subjects: 323
Study: 37225265

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg two times a day for 14 days)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Vitamin C and Placebo
Number of subjects: 464
Study: 37225266

Group type: EXPERIMENTAL
Intervention: Dry needling (DN) - ultrasound-guided intramuscular and interfascial DN 8-10 times per pain point or until local twitch responses are no longer elicited, with 30 minutes of indwelling.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) - ultrasound-guided intramuscular (0.9% saline 2 mL, 42℃, 2 Hz, 2 min) and interfascial (0.9% saline 5 mL, 42℃, 2 Hz, 2 min) PRF.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 108
Study: 37225267

Group type: EXPERIMENTAL
Intervention: Web-based routine outcome monitoring system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sociodemographic information and satisfaction with treatment data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with therapists and trainees
Number of subjects: 0
Study: 37225277

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus Dexamethasone Palmitate (DXP) emulsion
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus DXP
Number of subjects: 124
Study: 37225309

Group type: EXPERIMENTAL
Intervention: Cryoballoon PVI+PWI
Number of subjects: 320

Group type: COMPARATOR
Intervention: Cryoballoon PVI
Number of subjects: 320
Study: 37225552

Group type: EXPERIMENTAL
Intervention: Concomitant therapy with 20 fractions of radiotherapy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Concomitant therapy with 32 fractions of radiotherapy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Gemcitabine in 32 fractions of radiotherapy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Concomitant therapies in both 20 and 32 fractions of radiotherapy
Number of subjects: 345
Study: 37225662

Group type: EXPERIMENTAL
Intervention: Osteopathic medical care (OMC)
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Allopathic medical care
Number of subjects: 1079
Study: 37225710

Group type: EXPERIMENTAL
Intervention: Closed-loop neuromodulation treatment
Number of subjects: 2
Study: 37225777

Group type: EXPERIMENTAL
Intervention: Silicone double-lumen tube (DLT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyvinyl single-lumen tube (SLT)
Number of subjects: 80
Study: 37226050

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37226141

Group type: EXPERIMENTAL
Intervention: CHAMPS intervention (CleverCap pill bottle synced to WiseApp)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard-of-care (control)
Number of subjects: 300
Study: 37226144

Group type: EXPERIMENTAL
Intervention: PsicAP group cognitive-behavioral training intervention, consisting of 7 group sessions lasting 1.5 hours each.
Number of subjects: 0
Study: 37226150

Group type: EXPERIMENTAL
Intervention: BD P+ (patients with psychotic symptoms)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: BD P+
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: BD I and BD II groups
Number of subjects: 520
Study: 37226174

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 350

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 350
Study: 37226208

Group type: EXPERIMENTAL
Intervention: High dose frequency (4 times per week for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low dose frequency (2 times per week for 12 weeks)
Number of subjects: 60
Study: 37226210

Group type: EXPERIMENTAL
Intervention: PMHC-treatment
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Older clients
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Unemployed clients
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Poor social support
Number of subjects: 526
Study: 37226214

Group type: EXPERIMENTAL
Intervention: Music intervention in addition to standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading intervention in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study: 37226224

Group type: EXPERIMENTAL
Intervention: IMCY-0098 (50/150/450 μg for priming followed by 25/75/225 μg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 37226252

Group type: EXPERIMENTAL
Intervention: Immediate endoscopic necrosectomy (DEN) initiated during or within 72 hours of EUS-guided drainage.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Drainage-oriented step-up approach with on-demand DEN after 72-96 hours observation.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Immediate endoscopic necrosectomy (DEN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Drainage-oriented step-up approach
Number of subjects: 70
Study: 37226261

Group type: EXPERIMENTAL
Intervention: Significant persistent pain (NRS ≥ 3)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Symptoms compatible with neuropathic pain (ID-pain score > 3)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Risk factors for persistent pain
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Specialist pain management
Number of subjects: 814
Study: 37226281

Group type: EXPERIMENTAL
Intervention: Complete Vocal Technique voice therapy (CVT-VT)
Number of subjects: 10
Study: 37226299

Group type: EXPERIMENTAL
Intervention: Telemedicine specialty referral
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard primary care referral
Number of subjects: 153
Study: 37226312

Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37226352

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37226448

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: HF alone
Number of subjects: 6263
Study: 37226504

Group type: EXPERIMENTAL
Intervention: SCB-2019 vaccine
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study: 37226519

Group type: EXPERIMENTAL
Intervention: CTPS1 inhibitor (STP938)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CRISPR CTPS1 knockout
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CTPS1 inhibition
Number of subjects: 105
Study: 37226772

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 37226826

Group type: EXPERIMENTAL
Intervention: Robotic-assisted nipple-sparing mastectomy (R-NSM)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Conventional nipple-sparing mastectomy (C-NSM)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Endoscopic-assisted nipple-sparing mastectomy (E-NSM)
Number of subjects: 231
Study: 37226884

Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Embolization (unruptured AVMs)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Embolization (ruptured AVMs)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Target embolization (unruptured AVMs)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Curative embolization (ruptured AVMs)
Number of subjects: 906
Study: 37226937

Group type: EXPERIMENTAL
Intervention: Multimodal hypersensitivity (MMH)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bladder hypersensitivity
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Principal component analysis of sensory testing measures
Number of subjects: 200
Study: 37227160

Group type: EXPERIMENTAL
Intervention: Acalabrutinib (n = 48)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined cohorts of BTKi-treated patients (n = 121)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CD49d+ cases
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CD49d- cases
Number of subjects: 121
Study: 37227176

Group type: EXPERIMENTAL
Intervention: SYNB1891 monotherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SYNB1891 in combination with atezolizumab
Number of subjects: 32
Study: 37227329

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: CMR-LVEF
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume index
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) mass
Number of subjects: 861
Study: 37227340

Group type: EXPERIMENTAL
Intervention: PFA (PULSE1)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PFA (PULSE2)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PFA (PULSE3)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: RF/PF catheter
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PULSE3 waveform
Number of subjects: 178
Study: 37227402

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desvenlafaxine
Number of subjects: 0
Study: 37227483

Group type: EXPERIMENTAL
Intervention: CT scan performed in 23 patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: Plain X-ray assessment
Number of subjects: 53
Study: 37227497

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft (FDBA) covered with collagen sponge (CS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft (FDBA) covered with free gingival graft (FGG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Demineralized bovine bone mineral xenograft (DBBM) covered with FGG
Number of subjects: 41

Group type: COMPARATOR
Intervention: FGG alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Xenograft vs Allograft
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Collagen sponge (CS) vs Free gingival graft (FGG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FDBA vs DBBM
Number of subjects: 41
Study: 37227536

Group type: EXPERIMENTAL
Intervention: Novel multielectrode array catheter
Number of subjects: 0
Study: 37227572

Group type: EXPERIMENTAL
Intervention: Tracked ultrasound (US) registration
Number of subjects: 18
Study: 37227726

Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban for 7 days (short prophylaxis)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban for 28 days (long prophylaxis)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban for both 7 and 28 days
Number of subjects: 272
Study: 37227734

Group type: EXPERIMENTAL
Intervention: Intraperitoneal olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy with or without bevacizumab
Number of subjects: 27
Study: 37227729

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor (Ticagrelor or Clopidogrel)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Usual care (no P2Y12 inhibitor)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Number of subjects: 949

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 949
Study: 37227758

Group type: EXPERIMENTAL
Intervention: Web-based KT tool
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham video
Number of subjects: 103
Study: 37227866

Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Structured Clinical Management (SCM)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Number of subjects: 78
Study: 37227937

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg administered before dialysis session initiation in kidney failure group.
Number of subjects: 2
Study: 37228005

Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring with elevated values triggering allograft biopsy and therapeutic adaptations.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Urine CXCL10 monitoring (results concealed).
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring with elevated values triggering allograft biopsy and therapeutic adaptations (per-protocol analysis).
Number of subjects: 241

Group type: COMPARATOR
Intervention: Urine CXCL10 monitoring (results concealed) (per-protocol analysis).
Number of subjects: 241
Study: 37228011

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 37228028

Group type: COMPARATOR
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 3225

Group type: COMPARATOR
Intervention: Intravenous belimumab 1 mg/kg
Number of subjects: 3225

Group type: COMPARATOR
Intervention: Subcutaneous belimumab 200 mg
Number of subjects: 3225

Group type: COMPARATOR
Intervention: Antimalarial agents (AMA)
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: Combination of intravenous belimumab 1 mg/kg and AMA
Number of subjects: 3225
Study: 37228030

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 37228142

Group type: EXPERIMENTAL
Intervention: Multifaceted environmental control intervention (dynamic light therapy, auditory masking, rationalization of ICU nocturnal patient care activities)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study: 37228726

Group type: EXPERIMENTAL
Intervention: Qualitative meta-synthesis based on patients' narratives from qualitative studies
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Qualitative meta-synthesis
Number of subjects: 167
Study: 37228786

Group type: EXPERIMENTAL
Intervention: Closed-loop central thalamic deep brain stimulation (CT-DBS)
Number of subjects: 0
Study: 37228816

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0